Up­dat­ed: Al­ny­lam faces DOJ probe over On­pat­tro mar­ket­ing

In the com­pet­i­tive mar­ket to sell drugs for the rare dis­ease hered­i­tary AT­TR amy­loi­do­sis, the Jus­tice De­part­ment thinks Al­ny­lam may have crossed a line.

Al­ny­lam dis­closed in an SEC fil­ing Mon­day that on April 9, the DOJ served the com­pa­ny with a sub­poe­na re­lat­ed to how they mar­ket­ed and pro­mot­ed On­pat­tro, their $300 mil­lion per year drug for the ge­net­ic nerve-af­flict­ing con­di­tion. The 3-sen­tence fil­ing of­fered vir­tu­al­ly no de­tails, ex­cept that they are co­op­er­at­ing, prepar­ing a re­sponse and have hired “ex­pe­ri­enced out­side le­gal coun­sel” to as­sist.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER